Amgen Inc. v. F. Hoffmann-LaRoche LTD et al
Filing
502
DECLARATION re #498 MOTION for Summary Judgment of No Obviousness-Type Double Patenting BY HARVEY F. LODISH, Ph.D. by Amgen Inc.. (Attachments: #1 Exhibit A#2 Exhibit B#3 Exhibit C#4 Exhibit D-1#5 Errata D-2#6 Exhibit D-3#7 Errata D-4#8 Exhibit E-1#9 Exhibit E-2 (part 1)#10 Exhibit E-2 (part 2)#11 Exhibit E-3#12 Exhibit E-4#13 Exhibit E-5 (part 1)#14 Exhibit E-5 (Part 2)#15 Exhibit E-5 (part 3)#16 Exhibit E-6)(Gottfried, Michael)
<![CDATA[
Amgen Inc. v. F. Hoffmann-LaRoche LTD et al
Doc. 502 Att. 7
Case 1:05-cv-12237-WGY
Document 502-8
Filed 06/14/2007
Page 1 of 2
EXHIBIT D-4
Lodish Decl to Motion for SJ re ODP - Public
Dockets.Justia.com
Case 1:05-cv-12237-WGY
Document 502-8
Filed 06/14/2007
Page 2 of 2
Table D-4
Original Group V Claims 55. A pharmaceutical composition comprising an effective amount of a polypeptide according to claims 1, 16, 39, 40, or 41 and a pharmaceutically acceptable diluent, adjuvant, or carrier.
`422 Pharmaceutical Composition Claims 1. A pharmaceutical composition comprising a therapeutically effective amount of human erythropoietin and a pharmaceutically acceptable diluent, adjuvant or carrier, wherein said erythropoietin is purified from mammalian cells grown in culture.
56. A method for providing erythropoietin therapy to a mammal comprising administering 2. A pharmaceutically-acceptable preparation an effective amount of a polypeptide according containing a therapeutically effective amount to claims 1, 16, 39, 40, or 41. of erythropoietin wherein human serum albumin is mixed with said erythropoietin. 57. A method according to claim 56 wherein the therapy comprises enhancing hematocrit levels.
]]>
Disclaimer: Justia Dockets & Filings provides public litigation records from the federal appellate and district courts. These filings and docket sheets should not be considered findings of fact or liability, nor do they necessarily reflect the view of Justia.
Why Is My Information Online?
